Orthostatic Hypotension Drugs Market

Global Orthostatic Hypotension Drugs Market Size, Share & Trend Analysis Report, By Product (Droxidopa, Fludrocortisone, Indomethacin, Midodrine Hydrochloride, NSAIDs, and Pyridostigmine), By Test Type (Blood tests, ECG, Echocardiogram, and Stress test), By End-Use (Ambulatory Surgical Centers, Clinics, Diagnostic Centers, and Hospitals), Forecast (2021-2027)

Published: Jan 2022 | Report Code: OMR2025374 | Category : Pharmaceuticals | Delivery Format: /

The global orthostatic hypotension drugs market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Orthostatic hypotension, which is also known as postural hypotension, is a state of dizziness, that is caused due to low blood pressure. This commonly happens when a person stands up from a long sitting and feel dizzy. Orthostatic hypotension can be caused due to dehydration, heart problems, endocrine problems as well as nervous system disorders. Moreover, it has been found that nursing home elderly residents are more prone to orthostatic hypotension than people who stay living in the community.

The orthostatic hypotension disorder is most common in the elderly, teenagers and postpartum mothers. The major factors that are expected to fuel the global orthostatic hypotension market include the increasing aging population and increase in the prevalence of diabetes and heart disorders, along with the availability of an increasing number of treatments options. Moreover, increasing adoption and integration of technologies in healthcare premises along with the emergence of new entrants in the existing market are also the factors that are anticipated to boost the demand for treatment of orthostatic hypotension globally. The global orthostatic hypotension drugs market analysis includes some of the key market players such as Mylan Inc, Upsher-Smith Laboratories, Chelsea Therapeutics, Amgen, F. Hoffman-La Roche, and Apotex, Inc., among others. 

Market Coverage

  • The market number available for – 2020-2027
  • Base year- 2020
  • Forecast period- 2021-2027
  • Segment Covered
  • Regions Covered- Globally

Competitive Landscape: Mylan Inc, Upsher-Smith Laboratories, Chelsea Therapeutics, Amgen, F. Hoffman-La Roche, and Apotex, Inc., among others.

Key questions addressed by the report

  • What is the market growth rate?
  • Which segment and region dominates the market in base year?
  • Which segment and region will project fastest growth in the market?
  • How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

  • Who is the leader in the market?
  • How players are addressing challenges to sustain growth?
  • Where is the investment opportunity?

Global Orthostatic Hypotension Drugs Market by Segment

By Product 

Droxidopa

Fludrocortisone

Indomethacin

Midodrine Hydrochloride

NSAIDs

Pyridostigmine

By Test Type 

Blood tests

ECG

Echocardiogram

Stress test

By End-Use 

Ambulatory Surgical Centers

Clinics

Diagnostic Centers

Hospitals

Global Orthostatic Hypotension Drugs Market by Region

North America

  • United States
  • Canada

Europe

  • UK
  • Germany
  • Italy
  • Spain
  • France
  • Rest of Europe 

Asia-Pacific

  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific 

Rest of the World